Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:30:33.354Z.
Consensus retrieved: 2026-10-06T09:12:43.421Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:30:33.354Z.
Quote observation: 2026-10-06T18:30:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69328368594ca01c79a1d7ac3810be200bc4ff9949d0867bb2c2a7ab20a5f204
Forward PE Ratio (N/A) = Dated Quote Price ($1.60) / Consensus Forward EPS ($-0.55)
FORWARD PE RATIO
N/A
Anavex Life Sciences Corp.
Market Cap
$148.62M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | $148.62M | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.69M | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $148.48M | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.33M | N/A |
| Codexis, Inc. (CDXS)vs › | $149.08M | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.98M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $150.43M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.93M | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $152.82M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
At the dated quote price of $1.60, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $-0.55 | $-0.55 – $-0.55 | 1 | n/m |
| 2028-09-30 | $2.27 | $2.27 – $2.27 | 1 | 0.7x |
| 2029-09-30 | $4.66 | $4.66 – $4.66 | 1 | 0.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
